| Host |
Mouse + Rabbit |
| Klon |
98/pp120 + EP6 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 + Rabbit IgG |
| Lokalisation |
Cytoplasm (p120) and cell membrane (E-Cadherin) |
p120 + E-Cadherin (LC/DC Breast Cocktail)
|
Biocare Medical |
98/pp120 + EP6 |
6 ml |
Ready-to-use |
CE/IVD |
API3011DSAA |
-
|
| Host |
Mouse |
| Klon |
98/pp120 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
1:100 - 1:250 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3008A |
-
|
| Host |
Mouse |
| Klon |
98/pp120 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
1:100 - 1:250 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nuclear |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3008B |
-
|
| Host |
Mouse |
| Klon |
98/pp120 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nuclear |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
6 ml |
Ready-to-use |
CE/IVD |
API3008AA |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate Carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit Ig |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
16 ml |
Ready-to-use |
RUO |
BRB035 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate Carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR046 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate Carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit Ig |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
6 ml |
Ready-to-use |
RUO |
RBG002 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit Ig |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
RBK002 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit Ig |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK002-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP134 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP134-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP134-05 |
-
|
| Host |
Rabbit |
| Klon |
13H4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate carcinoma. |
| Verdünnung |
1:150 |
| Isotyp |
IgG |
| Verdünnung |
Human AMACR (P504S) polypeptide |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
1 ml |
Concentrate |
CE/IVD |
Z2001RL |
-
|
| Host |
Rabbit |
| Klon |
13H4 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Human AMACR (P504S) polypeptide |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2001RP |
-
|
| Host |
Rabbit |
| Klon |
13H4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate carcinoma. |
| Verdünnung |
1:150 |
| Isotyp |
IgG |
| Verdünnung |
Human AMACR (P504S) polypeptide |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2001RS |
-
|
| Host |
Rabbit |
| Klon |
13H4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate carcinoma. |
| Verdünnung |
1:150 |
| Isotyp |
IgG |
| Verdünnung |
Human AMACR (P504S) polypeptide |
| Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2001RT |
-
|
| Host |
Mouse + Rabbit |
| Klon |
L26 + polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a & Rabbit Ig |
| Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
16 ml |
Ready-to-use |
RUO |
BMS026 |
-
|
| Host |
Mouse + Rabbit |
| Klon |
L26 + polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 |
| Isotyp |
Mouse IgG2a & Rabbit Ig |
| Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
1 ml |
Concentrate |
RUO |
CO002K |
-
|
| Host |
Mouse + Rabbit |
| Klon |
L26 + polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 |
| Isotyp |
Mouse IgG2a & Rabbit Ig |
| Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
0.5 ml |
Concentrate |
RUO |
CO002K-05 |
-
|
| Host |
Mouse + Rabbit |
| Klon |
L26 + polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a & Rabbit Ig |
| Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
6 ml |
Ready-to-use |
RUO |
COG002 |
-
|
| Host |
Mouse |
| Klon |
4A4 + XM26 + LL002 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a, IgG1, IgG3 |
| Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4 + XM26 + LL002 |
16 ml |
Ready-to-use |
RUO |
BMS051 |
-
|
| Host |
Mouse |
| Klon |
4A4+XM26+LL002 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, Colon Carcinoma |
| Verdünnung |
1:50 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
1 ml |
Concentrate |
RUO |
CO005K |
-
|
| Host |
Mouse |
| Klon |
4A4+XM26+LL002 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, Colon Carcinoma |
| Verdünnung |
1:50 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
0.5 ml |
Concentrate |
RUO |
CO005K-05 |
-
|
| Host |
Mouse |
| Klon |
4A4+XM26+LL002 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
6 ml |
Ready-to-use |
RUO |
COG005 |
-
|
| Host |
Mouse |
| Klon |
PD7/26/16+2B11+L26+PS1+DF-T1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil or B-cell lmyphoma or T-cell lymphoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 and Mouse IgG2 |
| Lokalisation |
Cell Surface |
pan Lymphoma Cocktail
|
Biocare Medical |
PD7/26/16+2B11+L26+PS1+DF-T1 |
6 ml |
Ready-to-use |
CE/IVD |
API3035AA |
-
|
| Host |
Mouse+Rabbit |
| Klon |
M2-7C10+M2-9E3+T311+SP6 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
MouseIgG2a+IgG2b/kappa+rabbit IgG |
| Lokalisation |
Nuclear, cytoplasmic |
Pan Melanoma + Ki-67
|
Biocare Medical |
M2-7C10+M2-9E3+T311+SP6 |
6 ml |
Ready-to-use |
CE/IVD |
PM362DSAA |
-
|
| Host |
Mouse+Rabbit |
| Klon |
M2-7C10+M2-9E3+T311+SP6 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
MouseIgG2a+IgG2b/kappa+IgG2b/kappa+rabbit IgG |
| Lokalisation |
Nuclear, cytoplasmic |
Pan Melanoma + Ki-67
|
Biocare Medical |
M2-7C10+M2-9E3+T311+SP6 |
25 ml |
Ready-to-use |
CE/IVD |
PM362DSH |
-
|
| Host |
Mouse |
| Klon |
M2-7C10+M2-9E3+T311 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 or pH 6.0 |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG2b+IgG2b+IgG2a |
| Lokalisation |
Cytoplasmic |
Pan Melanoma Cocktail-2
|
Biocare Medical |
M2-7C10+M2-9E3+T311 |
0.1 ml |
Concentrate |
CE/IVD |
CM178A |
-
|
| Host |
Mouse |
| Klon |
M2-7C10+M2-9E3+T311 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 or pH 6.0 |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+IgG2b+IgG2a |
| Lokalisation |
Cytoplasmic |
Pan Melanoma Cocktail-2
|
Biocare Medical |
M2-7C10+M2-9E3+T311 |
6 ml |
Ready-to-use |
CE/IVD |
PM178AA |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Cerebral Cortex |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Peptide human TrkA, aa777-796 |
| Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR176 |
-
|
| Host |
Rabbit |
| Klon |
EPR17341 |
| Format |
Concentrate |
| Reaktivität |
CH |
| Methode |
P, WB, IF |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Astrocytoma, Cerebral Cortex |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus |
| Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
pan Trk
|
Zytomed Systems GmbH |
EPR17341 |
0.1 ml |
Concentrate |
RUO |
RBK069-01 |
-
|
| Host |
Rabbit |
| Klon |
EPR17341 |
| Format |
Concentrate |
| Reaktivität |
CH |
| Methode |
P, WB, IF |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Astrocytoma, Cerebral Cortex |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus |
| Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
pan Trk
|
Zytomed Systems GmbH |
EPR17341 |
0.5 ml |
Concentrate |
RUO |
RBK069-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Cerebral Cortex |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
Peptide human TrkA, aa777-796 |
| Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP176 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Cerebral Cortex |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
Peptide human TrkA, aa777-796 |
| Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP176-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Cerebral Cortex |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
Peptide human TrkA, aa777-796 |
| Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP176-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP030 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP030-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP030-05 |
-
|
| Host |
Rabbit |
| Klon |
SP151 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Parathyroid glands |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the internal region of human PTH protein |
| Lokalisation |
Cytoplasm |
Parathyroid Hormone (PTH)
|
Zytomed Systems GmbH |
SP151 |
1 ml |
Concentrate |
RUO |
516-4514 |
-
|
| Host |
Mouse |
| Klon |
BGN/1F8 |
| Format |
Purified |
| Methode |
F, P, EL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptide corresponding to amino acids 1-34 of mature PTH conjugated to a proprietary carrier molecule |
Parathyroid Hormone (PTH)
|
Zytomed Systems GmbH |
BGN/1F8 |
200 µg |
Purified |
RUO |
616-0067 |
-
|
| Host |
Mouse |
| Klon |
ZM207 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Parathyroid. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
| Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
1.0 ml |
Concentrate |
CE/IVD |
Z2378ML |
-
|
| Host |
Mouse |
| Klon |
ZM207 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Parathyroid. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
| Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
7 ml |
Ready-to-use |
CE/IVD |
Z2378MP |
-
|
| Host |
Mouse |
| Klon |
ZM207 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Parathyroid. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
| Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
0.5 ml |
Concentrate |
CE/IVD |
Z2378MS |
-
|
| Host |
Mouse |
| Klon |
ZM207 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Parathyroid. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
| Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
0.1 ml |
Concentrate |
CE/IVD |
Z2378MT |
-
|
| Host |
Rabbit |
| Klon |
ZR224 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Renal cell carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
| Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
1 ml |
Concentrate |
CE/IVD |
Z2741RL |
-
|
| Host |
Rabbit |
| Klon |
ZR224 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Renal cell carcinoma |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
| Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
7 ml |
ready-to-use |
CE/IVD |
Z2741RP |
-
|
| Host |
Rabbit |
| Klon |
ZR224 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Renal cell carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
| Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
0.5 ml |
Concentrate |
CE/IVD |
Z2741RS |
-
|
| Host |
Rabbit |
| Klon |
ZR224 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Renal cell carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
| Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
0.1 ml |
Concentrate |
CE/IVD |
Z2741RT |
-
|
| Host |
Rabbit |
| Klon |
SP34 |
| Format |
Concentrate |
| Reaktivität |
CK, DG, MS |
| Methode |
P, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
0.1 ml |
Concentrate |
RUO |
530-3340 |
-
|
| Host |
Rabbit |
| Klon |
SP34 |
| Format |
Concentrate |
| Reaktivität |
CK, DG, MS |
| Methode |
P, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
| Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
0.5 ml |
Concentrate |
RUO |
530-3342 |
-
|